3. Results
TB, sepsis
SEPSIS
Immediate empiric-therapy demonstrated favorable cost-effectiveness compared with all three diagnosis-dependent standard of care models (urine TB-LAM, sputum Xpert MTB/RIF, and the combination LAM/Xpert). Of the three cost effectiveness models, the sputum Xpert diagnostic strategy presented the most favorable incremental effectiveness of early empiric treatment compared with the standard approach (0.08) and ICER (USD 2021.26); followed by urine LAM incremental effectiveness (0.05) and ICER (USD 2683.19); and combined LAM/Xpert incremental effectiveness (0.03) and ICER (USD 4269.73). In sensitivity analysis, the parameter that contributed the most to increased effectiveness of the immediate empiric anti-TB treatment strategy was the proportion of those persons treated with immediate anti-TB treatment who had rifampin susceptible TB, followed by the proportion alive at day seven among those who presented with symptoms of sepsis but who were not found to have diagnostic confirmation of TB, and lastly the proportion of those with rifampin resistance (